UCSF Helen Diller Family Cancer Center
Welcome,         Profile    Billing    Logout  
 10 Trials 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hermiston, Michelle
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Calendar Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL
Active, not recruiting
2
121
Europe, Canada, US
CTL019
Novartis Pharmaceuticals, Children's Oncology Group
B-Cell Acute Lymphoblastic Leukemia
10/27
10/27
NCT04551131: Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Active, not recruiting
1/2
62
US
Ruxolitinib, Jakafi®, Dexamethasone, Decadron®, Hexadrol®, Dexone®, Dexameth®, Etoposide, Etoposide Phosphate, VePesid®, Etopophos®, VP-16
St. Jude Children's Research Hospital, Incyte Corporation, North American Consortium for Histiocytosis, Cures Within Reach
Hemophagocytic Lymphohistiocytosis
08/25
08/26
NCT02879643: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

Recruiting
1
36
Canada, US, RoW
Marqibo
Therapeutic Advances in Childhood Leukemia Consortium, Spectrum Pharmaceuticals, Inc
ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
08/21
12/22
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 

Download Options